Joshua N. Silverman - 24 Nov 2021 Form 4 Insider Report for MyMD Pharmaceuticals, Inc. (TNFA)

Role
Director
Signature
/s/ Joshua Silverman
Issuer symbol
TNFA
Transactions as of
24 Nov 2021
Net transactions value
+$103,358
Form type
4
Filing time
29 Nov 2021, 11:46:33 UTC
Previous filing
15 Oct 2021
Next filing
07 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MYMD Common Stock Purchase $42,418 +6,734 +9.1% $6.30 80,509 24 Nov 2021 Direct F1
transaction MYMD Common Stock Purchase $23,168 +3,266 +4.1% $7.09 83,775 24 Nov 2021 Direct F2
transaction MYMD Common Stock Purchase $37,772 +5,000 +6% $7.55 88,775 26 Nov 2021 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.97 to $6.96, inclusive. The reporting person undertakes to provide to MyMD Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), and (3) to this Form 4.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.17, inclusive.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.07 to $7.70, inclusive.